Articles tagged with Cancer Medication
A study found that adding cetuximab to a regimen of drugs after stage III colon cancer surgery did not improve disease-free survival. The trial tested the combination in patients with resected stage III wild-type KRAS colon cancer and showed no benefit.
Scientists at Fox Chase Cancer Center have discovered compounds that enhance the effects of gemcitabine, improving its ability to kill pancreatic cancer cells. This breakthrough could lead to a lower dose of chemotherapy with fewer side effects, potentially increasing survival rates for patients.
Scientists at Fox Chase Cancer Center found that defects in ribosomal proteins can lead to blood and other cancers. Inactivating L22, a key protein, triggered changes in cell signaling pathways associated with inflammation, which may be targeted for cancer treatment.
A new non-invasive technology, stool DNA (sDNA) testing, is being studied in a five-year clinical trial to detect colon cancer in its earliest stages. The test aims to improve colon cancer screening rates and decrease mortality from the deadly disease by complementing colonoscopy.
Dr. Eric N. Olson, chairman of molecular biology at UT Southwestern Medical Center, has been awarded the 2012 Steven C. Beering Award for his work on major genetic pathways controlling heart and muscle formation. Several drugs based on his research are currently under study.
A Mayo Clinic-led study has found that a combination of the novel drug TH-302 with standard drug gemcitabine delays cancer worsening in patients with advanced pancreatic cancer. The 2-drug combo showed a 5.6-month progression-free survival, significantly extending the average survival of six to seven months.
A study by UCLA's Jonsson Comprehensive Cancer Center found that patients with both MEK1 and BRAF mutations respond equally well to BRAF inhibitor drugs, challenging conventional wisdom. The presence of both mutations does not contribute to drug resistance in melanoma patients.
Scientists at WashU Medicine are using DNA sequencing to map the genetic evolution of disease and monitor response to treatment. By analyzing tumor samples, they can identify 'driver' mutations and determine whether cells carrying those mutations have been eliminated by treatment.
Researchers identified pazopanib as a clinically meaningful treatment for refractory urothelial cancer. The study found that increases in interleukin-8 levels after treatment predicted a lack of tumor response, with 10% of patients experiencing long-term cure.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
Researchers found that metformin reduces the level of glucose and inhibits fatty acid synthesis in mice, resulting in significantly fewer and smaller liver tumors. The drug has been linked to reduced risk of liver cancer in patients with Type II diabetes and obesity.
According to Washington University public health researchers, more than half of all cancer is preventable through lifestyle choices and societal changes. The main obstacles to implementing these strategies include skepticism, short-term focus, intervening too late in life, research focusing on treatment rather than prevention, debate a...
A large-scale study has identified hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. The research may lead to more effective treatments for childhood bone cancer, such as Ewing's sarcoma, by targeting specific genetic markers.
The Cancer Cell Line Encyclopedia offers a comprehensive resource for cancer research, integrating gene expression, chromosomal copy number, and pharmacological profiles. This will enable researchers to predict drug sensitivity and improve the success rate of drug development in personalized medicine.
The Cancer Cell Line Encyclopedia provides comprehensive genetic and molecular information for nearly 1,000 human cancer cell lines. This publicly available data may help researchers identify patients who could benefit from specific drugs and advance cancer research.
Patients with high-risk GI tumors who received imatinib for 3 years instead of 1 year had improved recurrence-free survival and overall survival. The study found that longer treatment with the cancer drug resulted in better survival outcomes and fewer patients discontinued treatment due to adverse effects.
Researchers used nanoparticles and magnetic fields to kill head and neck cancerous cells in mice without harming healthy cells. The treatment induced hyperthermia, raising the body temperature of only the concentrated nanoparticles within the tumor site.
A Purdue University biochemist is creating maps of all the potential routes for cancer cell formation, which could lead to more effective cancer drugs. By identifying kinases and their direct protein targets, researchers can tailor kinase-inhibiting drugs to block multiple pathways and make them more effective.
Stanford researchers found a disconnect between reported cardiac toxicities in journal articles and FDA labeling for sunitinib, a kidney cancer treatment. The authors argue that the current method of measuring adverse events is inadequate, leading to under-reporting of side effects.
A Purdue University scientist has developed a way to encase nutritional supplements in food-based products, protecting them from degradation due to heat, light, oxygen, and other external factors. The method involves creating crystalline-like fibers that embed the nutraceuticals, allowing for improved stability and bioavailability.
Researchers have discovered that a specific protein called p21 can kill certain cancer cells, including sarcomas, by sensitizing their mitochondria to oxidants. This finding provides a rationale for testing existing drugs that increase p21 levels in these types of cancers.
Researchers discovered a two-step ritual in which RNA telomerase partners are prepared for interaction, revealing novel pharmaceutical approaches to cancer and diseases of aging. The study sheds light on the complex process of telomerase biogenesis and its connection to seemingly unrelated diseases.
Researchers found low LDL cholesterol in patients with no history of cholesterol-lowering drugs existed before cancer diagnosis, suggesting an underlying mechanism. The study's lead investigator noted that the relationship between low LDL-C and cancer exists for many years prior to diagnosis, highlighting the need for further examination.
A phase III clinical trial found that the combination of everolimus and exemestane improved bone strength and reduced the chance of cancer spreading in the bone. The treatment also showed a lower rate of further tumour growth and more difficult metastases to occur.
Researchers discovered a DNA damage marker, telomeric allelic imbalance (tAI), that predicts sensitivity to platinum-based chemotherapy in patients with triple-negative breast cancer. The study found an inverse relationship between tAI and BRCA1 expression levels.
Scientists have identified a genetic marker that predicts which breast and ovarian cancers will respond to platinum-based chemotherapies. The marker, found on chromosomes within cancer cells, flags tumors unable to repair DNA damage caused by platinum agents, offering new hope for aggressive triple-negative breast cancer patients.
A national survey of OB-GYNs found that most doctors do not routinely ask about sexual problems or satisfaction, and even fewer inquire about a patient's orientation. This omission can lead to missed opportunities for diagnosis and treatment, with women often suffering in silence due to fear or embarrassment.
A recent study published in the Annals of Behavioral Medicine reveals that survivors of multiple cancers exhibit poorer physical and mental health status compared to those with a single cancer diagnosis. These individuals also engage in more unhealthy behaviors, such as smoking and excessive alcohol consumption.
Researchers at Johns Hopkins Kimmel Cancer Center discovered that low doses of epigenetic-targeted drugs azacitidine and decitabine can re-activate genes that stop cancer growth. The study found antitumor responses in breast, lung, and colon cancers, with effects caused by alteration of the epigenetic environment of DNA.
Researchers say forcing dying cancer cells to trigger an immune response could prevent cancer relapses and improve treatment benefits. The new strategy focuses on autophagy, a process that alerts the immune system to foreign invaders.
Two studies suggest that opioids can stimulate tumor growth and spread in cancer patients, with laboratory research indicating the mu opioid receptor plays a key role. Medications blocking this receptor may reduce cancer growth and metastasis.
Researchers at Sanford-Burnham Medical Research Institute found that MLN4924-resistant cancer cells escape death due to a simple mutation in the NEDD8-activating enzyme. The team developed a method to predict how cancer patients will respond to this drug, providing a new path toward personalized medicine.
A new method detects cancer-causing chromosomal translocations quickly and accurately, allowing for potential single-array testing for every known cancer-causing translocation simultaneously. The technique combines microarray technology with a novel antibody to detect the presence of the translocation.
Researchers have found that a new drug called plerixafor can help drive leukemia cells out of the bone marrow and into the bloodstream, making them more vulnerable to chemotherapy. In a clinical trial, 46% of patients with acute myeloid leukemia achieved complete remission after treatment.
A study found that a genetic variation in the BIM gene variant occurs in about 15% of the typical East Asian population and contributes to some patients' failure to benefit from tyrosine kinase inhibitor drugs. The researchers identified a novel class of BH3-mimetics as a potential treatment option to overcome this resistance.
Fox Chase Cancer Center is leading efforts to establish national standards for survivorship care, citing the need for comprehensive plans and guidelines. The Center's own survivorship care plan will be tailored to each patient, summarizing therapy and making recommendations based on their specific case.
New monoclonal antibody drugs are being tested in most tumor types, allowing them to bind to multiple targets and stimulate the immune response. Researchers have developed advanced antibody engineering techniques to create more effective treatments, including bispecific antibodies and conjugates with toxic payloads.
Researchers have identified a critical link in the signaling pathway that enables cancer cells to establish tumors in distant parts of the body. A new drug targeting this molecule may help prevent cancer from spreading, offering hope for improved treatment options.
Scientists have identified a new compound, Factor Qunolinone Inhibitor 1 (FQI1), that rapidly kills hepatocellular carcinoma (HCC) cells by inhibiting an oncogene, while sparing healthy tissue. Laboratory experiments and mouse models demonstrate the compound's effectiveness without observable toxicity.
A recent study found that the protein Mer resides in the nucleus of leukemia cells, suggesting it may influence gene expression and contribute to cancer development. This discovery opens up new avenues for targeted treatments and potentially more accurate diagnoses.
Researchers at WashU Medicine found that lifestyle interventions can slow weight gain and improve blood pressure in high-risk, low-income patients. Despite modest six-month weight losses, participants who received lifestyle intervention maintenance over two years experienced significant improvements in blood pressure control.
The largest-ever study of childhood Acute Lymphoblastic Leukemia (ALL) reveals a remarkable improvement in the five-year survival rate, increasing from 83.7% in 1990-1994 to 90.4% in 2000-2005. This significant advancement is attributed to better treatment and drug optimization, not the introduction of new drugs.
A study published in Archives of Internal Medicine found that higher red meat consumption is associated with an increased risk of all-cause mortality, cardiovascular disease, and cancer. Substituting other protein sources like fish, poultry, and legumes can lower this risk.
A team of researchers has found that an antidepressant called tranylcypromine (TCP) can harness the power of a vitamin A-derivative to treat acute myeloid leukemia (AML). The study reveals that inhibiting an enzyme called LSD1 with TCP can switch genes on, making cancer cells susceptible to ATRA.
Researchers identified ways to reduce costs of molecular profiling and targeted therapies, enabling more patients to benefit from personalized treatments. The methods include recommending testing only for high-risk patients and merging tests to lower combined prices.
Wilmot researchers develop first genetically engineered mouse model for Intrahepatic Cholangiocarcinoma (IHCC), a type of bile duct cancer. The model incorporates common mutations in humans and enables testing of potential treatments, accelerating the discovery process.
The Damon Runyon Cancer Research Foundation launched its Accelerating Cancer Cures program, a five-year initiative to train exceptional clinical investigators and foster collaboration between academia and industry. The program aims to address the critical shortage of clinical researchers working on breakthroughs in cancer treatments an...
A University of Colorado Cancer Center investigator has received a prestigious grant to develop targeted treatments for squamous cell lung cancer. The project aims to identify prognostic signatures and molecular targets for early-stage patients, paving the way for personalized cancer care.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered a mechanism by which melanoma becomes resistant to the BRAF inhibitor Zelboraf. By amplifying the mutated BRAF gene, cancer cells can overproduce the drug target protein, rendering the treatment ineffective.
Scientists at University of California, San Diego have identified ROR1 as a protein expressed by breast cancer cells but not normal adult tissues. Silencing its expression impairs tumor growth and survival, making it a potential therapeutic target for future anti-cancer drugs.
A phase I clinical trial of patients with advanced pancreatic cancer showed promise with rigosertib, achieving stable disease in 11 of 19 patients for a median duration of 113 days. The drug targets PLK1 and PI3K signals that allow cancer cells to divide rapidly.
The new drug Vemurafenib doubles the median survival time of metastatic melanoma patients with a specific genetic mutation, from 6 months to 15.9 months. In responding patients, the drug stops cancer progression for an additional 6.7 months.
A new phase-3 trial confirms that ruxolitinib reduces spleen volume and alleviates symptoms in patients with intermediate or advanced myelofibrosis. The study, led by Stanford Medicine, found significant improvements in patients taking the drug compared to those on placebo.
A phase III clinical trial shows that ruxolitinib relieves severe symptoms and extends survival in patients with myelofibrosis. The drug also shrinks swollen spleens, a hallmark of the disease, and improves quality of life for many patients.
A study by Vall d'Hebron Institute of Oncology reveals a potential new strategy to boost efficacy and break down resistance in patients with HER2 positive breast cancer. The combination of two drugs shows promise as a third treatment option, offering hope for patients with advanced tumours.
A Scripps Clinic study found that sleeping pill users are at a 4.6 times higher risk of death, with rates of new cancers being 35% higher among regular users. The research suggests alternatives to hypnotic medications and emphasizes the importance of treating underlying psychological disorders.
A new study found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience significant long-term benefits when switching to imatinib. Up to 93% of patients survive at least eight years, compared to only three to six years prior to imatinib.
A matched cohort study found that certain commonly prescribed sleeping pills are associated with a significantly increased risk of death and cancer among users. The study linked these drugs to a more than fourfold increased risk of death, even at relatively low doses.
Scientists at UCSF found simultaneous targeting of two molecules can effectively shrink tumors, block invasion, and stop metastasis in mice. The approach may improve combination treatments, including drugs like Avastin, for various cancer types.